BioTime (BTX) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
Go back to BioTime (BTX) Misses Q1 EPS by 5c
May 10, 2016 5:01 PM EDT
- First Cohort in OpRegen® Trial Completed
- Management to Host Investor Conference Call on May 17, 2016 at 4:30
p.m. ET
ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative
medicine company with a focus on pluripotent stem cell technology, today
reported financial results for the first quarter ended March 31, 2016
and provided a corporate update. The Company also announced that
management will host a conference call with investors to discuss the
recent operating progress and corporate... More
May 10, 2016 9:29 AM EDT
FREMONT, Calif., May 10, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced the pricing of an underwritten public offering of 5,147,059 units at a public offering price of $3.40 per unit. Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of common stock at an exercise price of $4.37 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The... More
